Sanofi completes $470m Vigil acquisition

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Big pharma plans Phase 2 Alzheimer’s trial of Vigil’s oral TREM2 agonist designed to convert microglia into their neuroprotective state.

Pharma giant Sanofi has completed its acquisition of Vigil Neuroscience, aiming to bolster its early-stage neurology portfolio with assets focused on neurodegenerative diseases. The deal will see Vigil’s lead drug candidate, VG-3927, an oral small-molecule TREM2 agonist, enter into a Phase 2 trial for Alzheimer’s disease and folds the biotech’s research capabilities into Sanofi’s broader effort to apply immunology to central nervous-system disorders.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

Old dogs, new funding: Dog Aging Project fetches $29m from NIH

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE